Founded in Germantown, United States, Senseonics Holdings, Inc. is a medical technology company dedicated to revolutionizing diabetes management. The company's core mission is to improve the lives of people with diabetes through innovative glucose monitoring solutions. Senseonics designs, develops, and commercializes continuous glucose monitoring (CGM) systems, with a particular focus on long-term implantable devices. Their flagship product, the Eversense CGM system, offers continuous glucose monitoring for up to 90 days with a single sensor, setting it apart in the market.
Notable figures affiliated with Senseonics include key medical and technological experts who have driven the company's innovations. The company has attracted significant investment from healthcare-focused venture capital firms and strategic partners. Senseonics has achieved several milestones, including FDA approval for its Eversense CGM system and expanding its market presence internationally. The impact of Senseonics' technology is profound, offering a more convenient and reliable glucose monitoring option that enhances the quality of life for individuals with diabetes.
